Drug intelligence / Profile preview

HXN-1021

Development stage: Preclinical
Lead developer: Earendil
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HXN-1021 is a monoclonal antibody developed by Earendil Labs (Helixon) that targets the OX40 ligand (OX40L). By binding to OX40L, the drug inhibits the interaction between OX40L on antigen-presenting cells and the OX40 receptor on T cells. This blockade modulates T cell co-stimulation, particularly the activation and expansion of effector T cells and the production of pro-inflammatory cytokines, thereby reducing skin inflammation associated with atopic dermatitis. It is currently in the preclinical candidate (PCC) stage of development.

Targets

TNFSF4 (Tumor necrosis factor ligand superfamily member 4)

Beyond the preview

Go deeper on HXN-1021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXN-1021.

Explore the full profile